COMPARATIVE ASSESSMENT OF GROWTH FACTORS EXPRESSION IN PIGMENT NEOPLASMS OF SKIN

DOI: https://doi.org/None

Ye.M. Frantsiyants, Ye.F. Komarova,V.A. Bandovkina, V.V. Pozdnyakova, N.D. Cheryarina Rostov Scientific and Research Institute of Oncology of the Ministry of Health of Russia, 14 line, 63, Rostov-on-Don, Russian Federation, 344037

Introduction. The study of growth factors in tissues of various kinds of nevi alongside with the skin melanoma can provide valuable information about the pathogenesis of the latter, determine the factors of early diagnostics of melanoma, as well as outline the ways of pathogenetically grounded therapy. The aim of the study. Studying the level of growth factors in cytosolic fraction of pigment nevi and skin melanoma tissues. Methods. The level of growth factors was studied by method of IFA in skin melanoma tissue samples (n=40) and nevi tissue samples (n=30), the factors being: vascular endothelial growth factor (VEGF) and its receptor (VEGF-R), epidermal grown factor (EGF) and its receptor (EGF-R), transforming one (TGF), fibroblasts growth factor (FGF), insulin-like growth factors 1 and 2 (IFR-1 and IFR-2). Results. It has been demonstrated that the tissue of nevi has particularities of metabolism distinguishing them both from melanoma tissue and from the intact skin tissue. So, the level of VEGF, EGF-R, TGF and IFR-2 in the tissue of nevi does not validly differ from the indicators in the intact skin, and the content of EGF, FGF, IFR-1 – from the indicators in the early stage melanoma tissue. Conclusions. The similarity of a number of indicators to those of early stage melanoma tissue gives grounds to suppose possible mechanisms of malignization of nevi.
Keywords: 
melanoma, nevus, growth factors
Список литературы: 
  1. Bosovskaya T.F., Marochko A.Yu., Mashenkina Ya.A., Kurpas E`.H. Kliniko-prognosticheskaya znachimost` molekulyarno-biologicheskih markerov supressii opuholevogo rosta, proliferacii i ih regulyatorov pri melanome kozhi. Dal`nevostochnyy medicinskiy zhurnal. 2010; 1: 119–22. [Bosovskaja T.F., Marochko A.Ju., Mashenkina Ja.A., Kurpas Je.H. Clinico-prognostic significance of molecular biomarkers suppression of tumor growth, proliferation, and their regulators in melanoma skin. Dal’nevostochniy Meditsinskiy zhurnal. 2010; 1: 119–22 (in Russian)]
  2. Parsunkova K.A. Citokinovyy profil` u bol`nyh s disseminirovannoy melanomoy v hode vakcinoterapii. Avtoref. diss. … kand. med. nauk. M., 2010. [Parsunkova K.A. Cytokine profile in patients with disseminated melanoma during vaccine therapy. Avtoref. diss. … kand. med. nauk. M., 2010 (in Russian)]
  3. Fererra M., Tsang C.S., Distel R.J. et al. TGF-β1 interactome: Metastasis and bejond. Cancer Genom. And Proteom. 2010; 7 (4): 217–29.
  4. Sachdev D., Yee D. Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther. 2007; 6: 1–12.
  5. Zhu X., Asa S.L., Ezzat S. Genetic and epigenetic mechanisms down-regulate FGF receptor 2 to induce melanoma-associated antigen A in breast cancer. Am. J. Pathol. 2010; 176 (5): 2333–43.
  6. Anisimov V.V., Vagner R.I., Barchuk A.S. Melanoma kozhi: Chast` 1. SPb: Nauka, 1995. [Anisimov V.V., Vagner R.I., Barchuk A.S. Melanoma skin: Part 1. SPb.: Nauka, 1995 (in Russian)]
  7. Lemehov V.G. E`pidemiologiya, faktory riska, skrining melanomy kozhi. Prakticheskaya onkologiya. 2001; 4 (8): 3–11. [Lemehov V.G. Epidemiology, risk factors, screening melanoma. Prakticheskaja onkologija. 2001; 4 (8): 3–11 (in Russian)]
  8. Groves M.D., Hess K.R., Puduvalli V.K., Colman H., Conrad C.A., Gilbert M.R., Weinberg J., Cristofanilli M., Yung W.K., Liu T.J. Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma. J. Neurooncol. 2009; 94 (2): 229–34.
  9. Linkous A., Yazlovitskaya E. Novel therapeutic approaches for targeting tumor angiogenesis. Anticancer Res. 2012; 32:1–12.
  10. Erwin M.E., Mueller K.L., Bohin N. et al. Lipid raft localization of EGFR alters the response of cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. J. Cell. Physiol. 2011; 226: 2316–28.
  11. Barreca A., De Luca M., Del Monte P., Bondanza S., et al. In vitro paracrine regulation of human keratinocyte growth by fibroblastderived insulin-like growth factors. J. Cell Physiol. 1992; 1 (2): 262–8.